FDA approves first mRNA seasonal flu vaccine
The US Food and Drug Administration has approved Moderna's mFlusiva, the world's first mRNA-based seasonal influenza vaccine, for adults aged 50 years and older, with full approval for ages 50–64 and accelerated approval for those 65 and above pending further studies. A Phase 3 trial of more than 40,000 adults found a 26.6% reduction in laboratory-confirmed influenza versus a standard licensed vaccine and stronger immune responses than Sanofi's high-dose vaccine in older adults. The approval highlights mRNA's potential for quicker design and production and could influence future influenza vaccine programs beyond the United States.
FDA approved Moderna's mFlusiva for adults aged 50 and older.
Context
mRNA vaccines were used widely during the COVID-19 pandemic. That success led to new mRNA flu vaccine development. Regulators and researchers will run follow-up studies and other countries may consider approvals.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Historical ParallelLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked